ARA-290 - 8MG

Log in to view pricing Apply for provider account
ARA-290 - 8MG
Availability:
Usually Ships in 24 Hours

Product Overview

ARA-290

ARA-290 (16 mg) is a non-erythropoietic peptide engineered from erythropoietin (EPO) that selectively engages the innate repair receptor (IRR; EPO-R/βcR heteromer) to trigger anti-inflammatory, neuroprotective, and pro-regenerative pathways without stimulating erythropoiesis.[1–3,8]

Neuroprotection & Anti-Inflammatory Actions

  • Inhibits Schwann-cell NLRP3 inflammasome, reduces NF-κB phosphorylation and ROS, and improves functional recovery after sciatic nerve crush in rats.[1]
  • Produces long-term relief of tactile/cold allodynia in neuropathic pain models; efficacy requires β-common receptor and is coupled to suppressed spinal microglial activation.[2,3]
  • Directly antagonizes TRPV1, contributing to analgesia and neuroprotection.[4]

Immune Modulation, Vascular Repair & Remyelination

  • Ameliorates experimental autoimmune neuritis/encephalomyelitis: ↓ IL-1β, IL-17, TNF-α, IFN-γ, iNOS, MMP9, T-bet; shifts toward Treg/Th2 and away from Th1/Th17; restrains inflammatory macrophage activation while enhancing phagocytosis.[5,6]
  • Promotes Schwann-cell proliferation and limits their inflammatory activation; supports remyelination and nerve regeneration.[1,5,6]

Clinical Evidence (Neuropathy & Metabolic)

  • Type 2 diabetes with painful neuropathy: 4 mg SC daily × 28 days improved neuropathic symptoms (PainDetect), increased corneal nerve fiber density, and favorably impacted HbA1c and lipids; well tolerated.[8]
  • Sarcoidosis-associated small fiber neuropathy: improvements in pain, corneal nerve fibers, sensory thresholds, and quality of life in clinical studies.[9]

Regenerative & Disease-Modifying Signals

  • In AD-like models, early systemic ARA-290 increased Ly6C+ patrolling monocytes, enhanced Aβ clearance, slowed pathology, and improved cognition.[10]

Key Takeaways

  • IRR-targeted cytoprotection: decouples tissue repair from erythropoiesis and cardiovascular risk.[2,8]
  • Multimodal efficacy: neuroinflammation downshift (NLRP3/NF-κB), nociceptor modulation (TRPV1), immune rebalancing (Treg/Th2), and vascular/nerve regeneration.[1–6]
  • Translational footprint: supportive preclinical results with early human signals in diabetic and sarcoid small-fiber neuropathy; additional trials warranted.[8,9]

References

  1. Liu G, Li W, Jiang S, et al. Eur J Pharmacol. 2025;997:177610. doi:10.1016/j.ejphar.2025.177610.[1]
  2. Swartjes M, Morariu A, Niesters M, et al. Anesthesiology. 2011;115(5):1084-92. doi:10.1097/ALN.0b013e31822fcefd.[2]
  3. Swartjes M, van Velzen M, Niesters M, et al. Mol Pain. 2014;10:13. doi:10.1186/1744-8069-10-13.[3]
  4. Zhang W, Yu G, Zhang M. Peptides. 2016;76:73-79. doi:10.1016/j.peptides.2016.01.003.[4]
  5. Liu Y, Luo B, Han F, et al. PLOS One. 2014;9(3):e90942. doi:10.1371/journal.pone.0090942.[5]
  6. Chen H, Luo B, Yang X, et al. J Neuroimmunol. 2014;268(1-2):64-70. doi:10.1016/j.jneuroim.2014.01.006.[6]
  7. Pulman KG, Smith M, Mengozzi M, et al. Neuroscience. 2013;233:174-183. doi:10.1016/j.neuroscience.2012.12.022.[7]
  8. Brines M, Dunne AN, van Velzen M, et al. Mol Med. 2015;20:658-66. doi:10.2119/molmed.2014.00215.[8]
  9. van Velzen M, Heij L, Niesters M, et al. Expert Opin Investig Drugs. 2014;23(4):541-50. doi:10.1517/13543784.2014.892072.[9]
  10. Al-Onaizi MA, Thériault P, Lecordier S, et al. Brain Behav Immun. 2022;99:363-382. doi:10.1016/j.bbi.2021.07.016.[10]

All information provided is for research purposes only.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.